Get the Stockscreener App
0.718
0.03%
0.0002
Geovax Labs Inc stock is traded at $0.718, with a volume of 196.93K.
It is up +0.03% in the last 24 hours and down -31.62% over the past month.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
See More
Previous Close:
$0.7178
Open:
$0.7181
24h Volume:
196.93K
Relative Volume:
0.04
Market Cap:
$3.74M
Revenue:
$852.30K
Net Income/Loss:
$-21.37M
P/E Ratio:
-0.0331
EPS:
-21.6981
Net Cash Flow:
$-19.06M
1W Performance:
-6.74%
1M Performance:
-31.62%
6M Performance:
-57.26%
1Y Performance:
-96.18%
1-Day Range:
$0.6928
$0.741
1-Week Range:
$0.69
$0.85
52-Week Range:
$0.6388
$20.00
Geovax Labs Inc Stock (GOVX) Company Profile
Name
Geovax Labs Inc
Sector
Industry
Phone
678-384-7220
Address
1955 LAKE PARK DRIVE, SMYRNA
Compare GOVX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOVX
Geovax Labs Inc
|
0.718 | 3.78M | 852.30K | -21.37M | -19.06M | -21.70 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Geovax Labs Inc Stock (GOVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Downgrade | D. Boral Capital | Buy → Hold |
| Apr-15-25 | Reiterated | Alliance Global Partners | Buy |
| Apr-15-25 | Reiterated | D. Boral Capital | Buy |
| Nov-11-24 | Initiated | Alliance Global Partners | Buy |
| Jul-16-24 | Initiated | ROTH MKM | Buy |
| Nov-19-20 | Initiated | Maxim Group | Buy |
View All
Geovax Labs Inc Stock (GOVX) Latest News
GeoVax Labs (GOVX): Armistice Capital and Steven Boyd disclose 4.99% stake - Stock Titan
GOVX Stock Became A Hot Biodefense Trade Amid Ebola, Hantavirus Concerns - Stocktwits
GeoVax Labs (GOVX) holders report 1.59% stake tied to 118,715 warrants - Stock Titan
GeoVax Highlights Capabilities Amid Congo's Expanding Ebola Outbreak - Yahoo Finance
GeoVax Labs, Inc. (GOVX) holders cap ownership at 4.99% with warrants - Stock Titan
GOVX: GEO-MVA targets a $1.3B vaccine market gap with expedited approval and scalable U.S. supply - TradingView
GeoVax Labs (NASDAQ:GOVX): What Could Today’s program progress and financing needs Update Reveal? - Kalkine Media
GeoVax Labs, Inc. (GOVX) Stock Price, News, Quote & History - Yahoo! Finance Canada
GeoVax targets Q4 phase 3 trial for MVA mpox vaccine with EMA expedited pathway - Proactive financial news
GeoVax Highlights Gedeptin(R) Tumor-Priming Strategy as Immuno-Oncology Enters New Phase - Yahoo Finance
Why Is GOVX Stock Falling Today? - Stocktwits
Jane Street Group discloses 4.3% GeoVax Labs (GOVX) ownership in updated 13G - Stock Titan
Health preparedness key as biological threats evolve - BioProcess International
GeoVax Announces Completion of Key GEO-MVA Development Milestones, Positioning Program for Pivotal Phase 3 Clinical Study - Yahoo Finance
GeoVax Labs Inc (GOVX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GeoVax Highlights Newly Published Independent Research Supporting Broader Filovirus Vaccine Strategies and Strategic Value of Its MVA-Based Vaccine Portfolio - Yahoo Finance
GeoVax Labs Inc (GOVX) Institutional Confidence - tradingkey.com
GeoVax Labs Inc (GOVX) Valuation: PE, PB & Fair Value Analysis - TradingKey
GeoVax Labs, Inc. 2026 Q2 Financial Report: Earnings, Losses & Key Financial Statements Overview - Minichart
GeoVax Advances GEO-MVA Pivotal Study Amid Strategic Reprioritization - citybuzz -
GeoVax Labs, Inc. Reports Q2 2026 Financial Results and Advances in Immuno-Oncology Programs - Minichart
GEOVAX LABS ($GOVX) Releases Q2 2026 Earnings - Quiver Quantitative
GeoVax Labs Inc reports results for the quarter ended June 30Earnings Summary - TradingView
GeoVax Reports Q2 2026 Net Loss of $4.4 Million - quiverquant.com
GeoVax Labs reports Q2 net loss $4.43M, cash ~$3.1M; advances GEO‑MVA pivotal study - TradingView
GeoVax Labs, Inc. 2026: Revenue $0 EPS ($0.97) — 10-Q Summary - TradingView
GeoVax Labs (GOVX) narrows loss but warns on cash runway and Nasdaq risk - Stock Titan
GeoVax Reports Second Quarter 2026 Financial Results and Provides Business Update - TradingView
GeoVax Labs Inc (GOVX) Cash Flow - TradingKey
GeoVax Labs Inc (GOVX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GeoVax Labs (GOVX) Earnings Date and Reports 2026 - MarketBeat
GeoVax Labs Inc (GOVX) Balance Sheet - TradingKey
GeoVax Labs Inc (GOVX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GeoVax Labs, Inc. Revenue Breakdown – NASDAQ:GOVX - TradingView
GeoVax Labs (GOVX) Tumbles 13% as Biotech Stock Tests Key Support at $0.69Earnings Breakout Stocks - dars.gov.et
GOVX|GeoVax Labs Inc|Price:0.755|Chg%:+0.024 - TradingKey
GOVX|GeoVax Labs Inc|Price:0.770|Chg%:+0.049 - TradingKey
GeoVax Labs Inc (GOVX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GeoVax Labs Inc (GOVX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GOVX|GeoVax Labs Inc|Price:0.733|Chg%:-0.107 - TradingKey
GeoVax Labs Inc expected to post a loss of $2.88 a shareEarnings Preview - TradingView
GeoVax Labs Inc (GOVX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GeoVax Highlights Strategic Alignment of GEO-MVA With HHS/ASPR's Five-Year Medical Countermeasure Preparedness Strategy - Yahoo Finance
GeoVax Labs (GOVX) Rallies Nearly 12% as Bulls Approach Key Resistance LevelPercent Below MA - dars.gov.et
GOVX stock soars 80%: Retail traders are piling in as Ebola, hantavirus risks resurface - MSN
GeoVax Labs(GOVX) Stock Options Chain | Quotes & News - Moomoo
GeoVax Labs Faces Nasdaq Noncompliance and Listing Risk - The Globe and Mail
GeoVax Labs, Inc. Receives Nasdaq Delisting Notice – Company Plans to Regain Compliance | 8-K Filing July 2026 - Minichart
GeoVax Labs Inc (GOVXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GEOVAX LABS INC (GOVX) Stock Chart - ChartMill
GeoVax Labs Received Notice of Noncompliance - TradingView
Geovax Labs Inc Stock (GOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):